<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121263</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 09-0657</org_study_id>
    <secondary_id>1RC1HL100951</secondary_id>
    <nct_id>NCT01121263</nct_id>
  </id_info>
  <brief_title>Hybrid Revascularization Observational Study</brief_title>
  <official_title>Hybrid Revascularization Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Center for Health Outcomes and Innovation Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to get a better understanding of patients who have multi-vessel
      coronary artery disease (blockages in more than one vessel bringing blood to the heart) and
      have either Hybrid Coronary Revascularization [HCR] (combination of surgery and catheter
      procedures to open up clogged heart arteries) or Percutaneous Coronary Intervention [PCI]
      (catheter procedures to open up clogged heart arteries). Participation in the study will last
      up to 21 months after a patient's heart procedure(s). The study collects information about
      the medical care patients receive during their planned procedure(s) and how well they do
      following the procedure(s). No new testing or procedures will be done. Patients will receive
      only the tests or procedures their doctor already has planned for them. The information
      collected should help to plan the design of a pivotal comparative effectiveness study of
      hybrid revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increasing prevalence of coronary artery disease (CAD), advances in coronary artery
      bypass grafting (CABG), percutaneous coronary intervention (PCI), and concomitant medical
      therapy, and the costs of revascularization have resulted in rising interest regarding the
      appropriate indications for coronary revascularization. For patients with 3-vessel disease,
      revascularization by CABG has recently been rated as appropriate while revascularization by
      PCI has been rated uncertain. Ideally, physicians would like to offer their multi-vessel CAD
      patients what they truly seek: a solution which provides a safe, minimally invasive treatment
      that does not compromise long term durability and survival. Integrating the positive features
      of both PCI and CABG has been the fundamental rationale of &quot;hybrid&quot; coronary
      revascularization.

      Hybrid Coronary Revascularization (HCR) (the intended combination of CABG and PCI) as a
      scientifically validated approach would have a major healthcare impact. The ability to
      deliver a new therapy for CAD that provides durability, but without the obligatory trauma and
      prolonged recovery time characteristic of conventional CABG would be a major advance in the
      field of cardiovascular medicine. Candidates in whom HCR would be particularly advantageous
      would be several subgroups of CAD patients that are increasing in numbers: the elderly,
      patients with a high predicted risk of mortality and/or morbidity for CABG, deconditioned
      patients or patients with significant disabilities and patients in whom treatment durability
      is important, but a significantly invasive approach is not an option. Moreover, HCR is likely
      to bridge the divide in treatment philosophies and approaches that exist between
      cardiologists and cardiac surgeons. Collaboration rather than competition between these
      specialties will ultimately benefit patients, hospitals, payers and healthcare providers. The
      Hybrid Revascularization Observational Study is a multi-center observational study planning
      grant which will explore target populations for Hybrid Coronary Revascularization (HCR),
      their outcomes, and variations in specific ways these patients are managed, in order to
      inform the design of a pivotal comparative effectiveness trial of this emerging therapeutic
      strategy.

      Given the observational nature of the study, the HCR and PCI groups' baseline characteristics
      and event rates are not directly comparable; rather, the results were intended to inform the
      design of a larger, randomized pivotal trial. The study was designed in two phases: Cohort 1,
      which captured demographic, angiographic, and practice patterns data for 6,669 consecutively
      screened patients; and Cohort 2 which captured demographic, angiographic, practice patterns,
      and outcome data for 298 patients who underwent either HCR or PCI with DES (90 of whom were
      also part of Cohort 1).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Event (MACCE)</measure>
    <time_frame>Month 12</time_frame>
    <description>For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
Death
Stroke
Myocardial Infarction
Repeat Revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Event (MACCE)</measure>
    <time_frame>Occurence of MACCE through the end of study up to two years</time_frame>
    <description>For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
Death
Stroke
Myocardial infarction
Repeat revascularization</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">298</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Angiogram Review Group</arm_group_label>
    <description>All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic Intervention Group</arm_group_label>
    <description>Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR
Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort 1 (Angiogram Review Group): All consecutive and consenting patients undergoing
        diagnostic cardiac catheterization in a 3 month period.

        Cohort 2 (Therapeutic Intervention Group): All patients (including those from cohort 1) who
        meet either of the following: (a) undergo HCR with minimally invasive LIMA-LAD CABG (HCR
        Group) OR (b) meet the proposed anatomic and clinical eligibility criteria defined below
        and undergo multivessel PCI with DES (PCI Group).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        The following criteria apply to Cohort 2 PCI patients only:

        Inclusion Criteria:

          -  Signed informed consent, release of medical information, and Health Insurance
             Portability and Accountability Act (HIPAA) documents

          -  Age 18 years or older

          -  Clinical indication for revascularization

          -  LAD and at least one additional vessel coronary disease (&gt; 70% stenosis) confirmed by
             angiogram

          -  Clinical characteristics and multi-vessel disease amenable to both PCI with DES and
             Hybrid as adjudicated by one interventional cardiologist and one cardiac surgeon

          -  Ability to tolerate and no plans to interrupt double platelet therapy for ≥ 12 months

          -  Ability to tolerate to single lung ventilation in the judgment of the investigator

          -  Willing to comply with all protocol required follow-up

        Exclusion Criteria:

          -  Previous coronary stent within:

               -  1 month prior to enrollment for bare metal stent (BMS) or

               -  6 months prior to enrollment for DES

          -  Evidence of in stent restenosis of a DES or BMS

          -  Previous cardiac surgery of any kind

          -  Chronic total occlusion (CTO) in LAD or ≥ 2 CTOs in major coronary territories that
             are considered targets for revascularization

          -  Left main disease ≥ 50% stenosis

          -  Presence of fresh coronary thrombus

          -  Need for concomitant vascular or other cardiac surgery during the index
             hospitalization (including, but not limited to, valve surgery, aortic resection, left
             ventricular aneurysm, carotid endarterectomy or stenting, etc)

          -  Previous STEMI within 30 days prior to randomization

          -  Previous stroke within 6 months prior to randomization

          -  Previous thoracic surgery involving the left pleural space

          -  Acute decompensated heart failure within 30 days prior to randomization

          -  Ejection fraction &lt; 30%

          -  Creatinine clearance ≤ 50 ml/min within 24 hours prior to randomization

          -  Hemodynamic instability at time of screening

          -  Body mass index &gt; 40

          -  Extra-cardiac illness that is expected to limit survival to less than 3 years

          -  Participation or planned participation in another investigational intervention study
             within 60 days prior to randomization

          -  Unable to give informed consent or potential for noncompliance with the study protocol
             due to psychiatric illness, organic brain disease, dementia, current alcohol abuse,
             mental retardation, language barrier, or geographical inaccessibility;

          -  Pregnancy at time of screening or intention to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Puskas, MD, MSc, FACS, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Ascheim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai (Data Coordinating Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph J DeRose, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Argenziano, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathew Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John G. Byrne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>November 25, 2013</results_first_submitted>
  <results_first_submitted_qc>November 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2014</results_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary arteriosclerosis</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>coronary artery bypass</keyword>
  <keyword>coronary artery bypass, off-pump</keyword>
  <keyword>coronary angiography</keyword>
  <keyword>drug-eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Recruitment started in May 2010 and completed in November 2011 across 11 US medical centers that included adult patients with multivessel coronary artery disease and clinical indication for revascularization, who were candidates for both Hybrid Coronary Revascularization (HCR) and Percutaneous Coronary Intervention (PCI) with DES</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 2: Intervention Cohort - HCR Group (N=200)</title>
          <description>Patients who underwent Hybrid Coronary Revascularization (HCR) with minimally invasive LIMA-LAD CABG</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Intervention Cohort - PCI Group (N=98)</title>
          <description>Patients who met proposed anatomic and clinical eligibility criteria and underwent multivessel Percutaneous Coronary Intervention (PCI) with drug eluting stents (DES)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 2: Intervention Cohort - HCR Group (N=200)</title>
          <description>Patients who underwent Hybrid Coronary Revascularization (HCR) with minimally invasive LIMA-LAD CABG</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Intervention Cohort - PCI Group (N=98)</title>
          <description>Patients who met proposed anatomic and clinical eligibility criteria and underwent multivessel Percutaneous Coronary Intervention (PCI) with drug eluting stents (DES)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.41" spread="11.78"/>
                    <measurement group_id="B2" value="63.91" spread="10.82"/>
                    <measurement group_id="B3" value="64.24" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac and Cerebrovascular Event (MACCE)</title>
        <description>For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
Death
Stroke
Myocardial Infarction
Repeat Revascularization</description>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HCR Group (N=200)</title>
            <description>Primary Outcome in Cohort 2: Intervention Cohort - HCR Group</description>
          </group>
          <group group_id="O2">
            <title>PCI Group (N=98)</title>
            <description>Primary Outcome in Cohort 2: Intervention Cohort - PCI Group</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac and Cerebrovascular Event (MACCE)</title>
          <description>For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
Death
Stroke
Myocardial Infarction
Repeat Revascularization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MACCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="0.666" upper_limit="1.697"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.666" upper_limit="1.697"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0.666" upper_limit="1.697"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0.666" upper_limit="1.697"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0.666" upper_limit="1.697"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This applies to any MACCE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazards regression model was weighted by propensity score to adjust for differences in baseline risk between the two groups.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.063</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.666</ci_lower_limit>
            <ci_upper_limit>1.697</ci_upper_limit>
            <estimate_desc>The Cox model was weighted by propensity score to adjust for differences in baseline risk between the two groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac and Cerebrovascular Event (MACCE)</title>
        <description>For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
Death
Stroke
Myocardial infarction
Repeat revascularization</description>
        <time_frame>Occurence of MACCE through the end of study up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HCR Group (N=200)</title>
            <description>Occurrence of MACCE through the end of study in Cohort 2: Intervention Cohort - HCR Group</description>
          </group>
          <group group_id="O2">
            <title>PCI Group (N=98)</title>
            <description>Occurrence of MACCE through the end of study in Cohort 2: Intervention Cohort - PCI Group</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac and Cerebrovascular Event (MACCE)</title>
          <description>For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:
Death
Stroke
Myocardial infarction
Repeat revascularization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MACCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This applies to any MACCE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.868</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.556</ci_lower_limit>
            <ci_upper_limit>1.355</ci_upper_limit>
            <estimate_desc>The Cox proportional hazards regression model was weighted by the propensity score to account for the difference in baseline risk between groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported throughout the period of trial participation for each study participant.</time_frame>
      <desc>Adverse events were documented and reported by staff at the study sites as they occurred per the protocol definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>HCR Group (N=200)</title>
          <description>Serious Adverse Events in Cohort 2: Intervention Cohort - HCR Group</description>
        </group>
        <group group_id="E2">
          <title>PCI Group (N=98)</title>
          <description>Serious Adverse Events in Cohort 2: Intervention Cohort - PCI Group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Diastolic Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dresseler's Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypertension Resulting in Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>IABP placed after becoming hypotensive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Revascularization</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute viral gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to antihypertensive drug</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Atypical Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Weakness and dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post op deliriums/psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia with bladder obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Percutaneous transluminal angioplasty of superficial femoral artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Revascularization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MSSM and sites shall cooperate in the submission of manuscript(s) for publication of the study results and sites shall not submit manuscripts for publication without express written permission of the Operations Committee. After dissolution of the Operations committee or one year after the completion of the agreement, whichever occurs first, no such permission shall be required.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah Ascheim, MD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-9567</phone>
      <email>deborah.ascheim@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

